<code id='E31DA989DF'></code><style id='E31DA989DF'></style>
    • <acronym id='E31DA989DF'></acronym>
      <center id='E31DA989DF'><center id='E31DA989DF'><tfoot id='E31DA989DF'></tfoot></center><abbr id='E31DA989DF'><dir id='E31DA989DF'><tfoot id='E31DA989DF'></tfoot><noframes id='E31DA989DF'>

    • <optgroup id='E31DA989DF'><strike id='E31DA989DF'><sup id='E31DA989DF'></sup></strike><code id='E31DA989DF'></code></optgroup>
        1. <b id='E31DA989DF'><label id='E31DA989DF'><select id='E31DA989DF'><dt id='E31DA989DF'><span id='E31DA989DF'></span></dt></select></label></b><u id='E31DA989DF'></u>
          <i id='E31DA989DF'><strike id='E31DA989DF'><tt id='E31DA989DF'><pre id='E31DA989DF'></pre></tt></strike></i>

          Home / knowledge / knowledge

          knowledge


          knowledge

          author:entertainment    Page View:32

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In